scholarly journals Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer

2016 ◽  
Vol 23 (3) ◽  
pp. 607-614 ◽  
Author(s):  
Michał Szczyrek ◽  
Radosław Mlak ◽  
Paweł Krawczyk ◽  
Kamila Wojas-Krawczyk ◽  
Tomasz Powrózek ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Small Cell Lung Cancer ◽  
Predictive Factor ◽  
Small Cell ◽  
Second Line ◽  
Multidrug Resistance Proteins ◽  
Small Cell Lung ◽  
Resistance Proteins ◽  
Genes Encoding

scholarly journals Expression of Multidrug Resistance Proteins and Accumulation of Cisplatin in Human Non-small Cell Lung Cancer Cells

2005 ◽  
Vol 28 (4) ◽  
pp. 707-712 ◽  
Author(s):  
Kenji Ikuta ◽  
Kazu Takemura ◽  
Kenichi Sasaki ◽  
Masaru Kihara ◽  
Masuhiro Nishimura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Lung Cancer Cells ◽  
Multidrug Resistance Proteins ◽  
Small Cell Lung ◽  
Resistance Proteins

Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer

2020 ◽  
Vol 9 (18) ◽  
pp. 1301-1309
Author(s):  
Longfeng Zhang ◽  
Xiaofang Zeng ◽  
Hongfu Cai ◽  
Na Li ◽  
Maobai Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Second Line ◽  
Small Cell Lung ◽  
The Cost ◽  
Quality Adjusted Life

Aim: To analyze the economic impact of nivolumab and chemotherapy in patients with non-small-cell lung cancer (NSCLC) who developed disease progression after platinum-containing dual-drug chemotherapy. Materials & methods: The partitioned survival model was used to analyze the cost-utility of two NSCLC treatments by nivolumab and docetaxel. The clinical data resulted from the Phase III clinical trial. The cost parameters were derived from our previous studies, and the utility parameters were derived from the literature. Results: The quality-adjusted life-years of nivolumab and docetaxel were 0.778 and 0.336. The lifetime direct medical expenses of nivolumab and docetaxel were US$44,707.17 and US$12,826.72. The incremental cost–effectiveness ratio was $72,127.71/quality-adjusted life-year. Conclusion: The combination of chemotherapy, nivolumab is not a cost-effective choice in the second-line treatment of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document